Lupus Nephritis Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com

Dallas, TX (PRWEB) June 10, 2015

The report “Lupus Nephritis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Lupus Nephritis. Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Lupus Nephritis with 31 market data tables and 15 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/lupus-nephritis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Lupus Nephritis – Pipeline Review, H1 2015 report include AbbVie Inc., Azano Pharmaceuticals Inc., Biogen, Inc., Bristol-Myers Squibb Company, Deltanoid Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., FibroStatin SL, GlaxoSmithKline plc, Invion Limited, Kadmon Corporation, LLC, Millennium Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Zyrnat Biotherapeutics SL.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are abatacept (recombinant), belimumab, BIIB-023, DP-001, Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis, FSMAB-26, INV-103, ixazomib citrate, KD-025, laquinimod sodium, Monoclonal Antibody for Lupus Nephritis, P-Dex, RO-5461111, venetoclax, voclosporin, Y-175L, ZY-11.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=390976 . (This is a premium report priced at US$ 2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers; Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers; Dec 11, 2014: Kadmon Corporation’s KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute; Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis; May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH; May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting; Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease; Oct 15, 2013: Kadmon Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH; Jun 12, 2013: Teva And Active Biotech Report Positive Results From Phase IIa Study Of Laquinimod In Active Lupus Nephritis.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=390976 . (This is a premium report priced at US$ 2000 for a single user License.)

List of Tables

Number of Products under Development for Lupus Nephritis, H1 2015 9

Number of Products under Development for Lupus Nephritis – Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Lupus Nephritis – Pipeline by AbbVie Inc., H1 2015 18

Lupus Nephritis – Pipeline by Azano Pharmaceuticals Inc., H1 2015 19

Lupus Nephritis – Pipeline by Biogen, Inc., H1 2015 20

Lupus Nephritis – Pipeline by Bristol-Myers Squibb Company, H1 2015 21

Lupus Nephritis – Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 22

Lupus Nephritis – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23

Lupus Nephritis – Pipeline by FibroStatin SL, H1 2015 24

Lupus Nephritis – Pipeline by GlaxoSmithKline plc, H1 2015 25

Lupus Nephritis – Pipeline by Invion Limited, H1 2015 26

Lupus Nephritis – Pipeline by Kadmon Corporation, LLC, H1 2015 27

Lupus Nephritis – Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 28

Lupus Nephritis – Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29

Lupus Nephritis – Pipeline by Zyrnat Biotherapeutics SL, H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Lupus Nephritis Therapeutics – Recent Pipeline Updates, H1 2015 74

Lupus Nephritis – Dormant Projects, H1 2015 98

Lupus Nephritis – Dormant Projects (Contd..1), H1 2015 99

Lupus Nephritis – Discontinued Products, H1 2015 100

Explore more reports on Renal therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.







Pharmaceutical
Related Pharmaceutical Press Releases

Leave a Reply